A memorable occasion for NACDS, mass retailing
Viewed from almost any perspective, December 13, 2023, was a significant day in the history of mass retailing in America.
Opinion
Health care outlook 2024: John O’Brien, president and CEO, NPC
In the second of a two-part series, leaders of industry associations present their expectations for pharmacy operators for this year. 2023 was a pivotal year for health policy, to say the least.
Health care outlook 2024: Scott Melville, president and CEO, CHPA
In the second of a two-part series, leaders of industry associations present their expectations for pharmacy operators for this year.
Health care outlook 2024: Micah Cost, CEO, PQA
In the second of a two-part series, leaders of industry associations present their expectations for pharmacy operators for this year. Former Defense Secretary Donald Rumsfeld once observed that “there are known knowns. There are things we know we know. We also know there are known unknowns.
Health care outlook 2024: Ronald Piervincenzi, CEO, U.S. Pharmacopeia
In the second of a two-part series, leaders of industry associations present their expectations for pharmacy operators for this year. The past year was significant for the pharmaceutical industry, as we witnessed major milestones and celebrated advancements in innovation.
Health care outlook 2024: Sheila Arquette, president and CEO, NASP
In the first of a two-part series, leaders of industry associations present their expectations for pharmacy operators for this year. The views of other organizations will appear in the next issue of Chain Drug Review. Specialty pharmacy continues to be dynamic, demanding and disruptive.
Health care outlook 2024: Sandra Hanna, CEO, Neighbourhood Pharmacies
In the first of a two-part series, leaders of industry associations present their expectations for pharmacy operators for this year. The views of other organizations will appear in the next issue of Chain Drug Review. 2023 was a momentous year for community pharmacy in Canada.
Health care outlook 2024: B. Douglas Hoey CEO, NCPA
In the first of a two-part series, leaders of industry associations present their expectations for pharmacy operators for this year. The views of other organizations will appear in the next issue of Chain Drug Review. The date January 1 can have varying meanings for people.
Health care outlook 2024: Lee Ann Stember, president and CEO, NCPDP
In the first of a two-part series, leaders of industry associations present their expectations for pharmacy operators for this year.
Health care outlook 2024: Peter Matz, director of Food, Pharmacy and Health Policy at FMI – The Food Industry Association
In the first of a two-part series, leaders of industry associations present their expectations for pharmacy operators for this year. The views of other organizations will appear in the next issue of Chain Drug Review.
Health care outlook 2024: Michael Hogue, CEO, APhA
In the first of a two-part series, leaders of industry associations present their expectations for pharmacy operators for this year. The views of other organizations will appear in the next issue of Chain Drug Review.
Health care outlook 2024: Susan Cantrell, CEO, AMCP
In the first of a two-part series, leaders of industry associations present their expectations for pharmacy operators for this year.
An Rx for an ailing health care system
As the start of a new year approaches, long-standing trends are raising the stakes for big pharmacy operators and other companies with the ambition to re-engineer a health care system plagued by chronic issues of access, quality and cost.
Don’t be late to celebrate NACDS’ 90th anniversary
This is an especially special holiday season for participants in and advocates of chain drug retailing in America. Reason? The season celebrates and pauses to recall the 90th anniversary of the National Association of Chain Drug Stores.
Understanding pharmacists’ discontent
Retail pharmacy has taken a beating in the press recently. Mainstream media outlets, including The New York Times, The Washington Post, CBS News and PBS, covered labor actions undertaken by pharmacists motivated by concerns about working conditions and potential risks to patients.